Brand-new Toronto transit station is finally about to open
New Toronto Transit Station to Open A new station serving GO Transit's Kitchener Line and UP Express is set to open in weeks. Metrolinx announced that the Mount Dennis GO and UP Sta…
Rates of Physician Attrition From Clinical Practice Have Risen Since 2013
Rates of Physician Attrition From Clinical Practice Have Risen Since 2013 A recent study found that the rate of physician attrition from c…
How to Navigate Complex Injury Cases Efficiently - GigWise
Navigating Complex Injury Cases Dealing with a serious injury case can be stressful and confusing, with nearly 70 percent of personal inju…
Study Claims Ozempic Lowers Biological Age | PharmExec
Study Claims Ozempic Lowers Biological Age Researchers reveal that GLP-1 medication Ozempic may reduce biological age, offering new hope i…
Valence-based Dracula Technologies secures €30M in Series A round to power IoT devices with light instead of batteries - Silicon Canals
Dracula Technologies Secures €30M in Series A Round Valence, France-based Dracula Technologies has announced the successful completion of …
Designing Light-Filled Living Spaces: How Lifestyle Remodeling Is Shaping the Future of Tampa Sunrooms
Designing Light-Filled Living Spaces In Florida, natural light is one of the state’s most abundant resources—and homeowners are increasing…
In the age of Ozempic, who gets it and who pays?
In the Age of Ozempic: Accessibility and Cost The effectiveness and cost of weight loss drugs like Ozempic, Wegovy, and Mounjaro have been…
Kymera Therapeutics, Inc.: Kymera Therapeutics Presents New Preclinical Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at the American College of Rheumatology Annual Meeting
Kymera Therapeutics Presents New Preclinical Data for KT-579 Kymera Therapeutics, Inc. announced the presentation of new preclinical data …
Neumora Therapeutics, Inc.: Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-898
Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study Neumora Therapeutics, Inc. has initiated a Phase 1 single-ascending do…
Which Non-League sides will take part in the Isuzu FA Trophy Second Round Proper? - The Non-League Football Paper
Isuzu FA Trophy Second Round Proper Draw Confirmed The draw for the Isuzu FA Trophy Second Round Proper has been announced, with 40 matche…
Food Ingredients Europe set for key return in Paris - Confectionery Production
Fi Europe 2025: A Key Return to Paris Registration is now open for Fi Europe 2025, celebrating its 30th edition in Paris from 2-4 December…